Factor XIs: Are they the Knockout Round in Next Phase Antithrombotic Therapies?-Will the Use of Factor XI Inhibitors Be a Unanimous or Split Decision?

Will the Use of Factor XI Inhibitors Be a Unanimous or Split Decision?

Video Transcription

Video Summary

In this session, Mark discusses the significance of Factor XI inhibitors in thrombosis management, especially given the unmet need related to events like stroke and acute coronary syndrome. Despite existing interventions, thrombosis remains a crucial area requiring attention. The excitement about Factor XI stems from studies showing that inhibiting it can reduce thrombotic risks without increasing bleeding. Mark outlines recent clinical trial phases focusing on different agents like Milvexian, Ascindexion, and Ablacemab, each showing various levels of efficacy and safety in conditions like atrial fibrillation and stroke prevention. While some trials like the Ascindexion faced setbacks, they provided learning opportunities about dosing and patient demographics. Ongoing trials continue to explore Factor XI's potential in broader medical conditions, offering hope for safer anticoagulation options. Insights from recent trials, such as those comparing bleeding risks, establish Factor XI's advantageous profile over current medications, reaffirming optimism for future applications.

Keywords

Factor XI inhibitors

thrombosis management

clinical trials

stroke prevention

anticoagulation